Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8736255 | 1.00 | HPGD (0.44) | HPGDL3MBTL1MAPTALDH1A1CYP1A2 | |
| SCHEMBL6328560 | 1.00 | HPGD (0.44) | HPGDL3MBTL1MAPTALDH1A1CYP1A2 | |
| SCHEMBL3370115 | 0.79 | HPGD (0.49) | HPGDL3MBTL1MAPTALDH1A1CYP1A2 | |
| SCHEMBL3370114 | 0.79 | HPGD (0.49) | HPGDL3MBTL1MAPTALDH1A1CYP1A2 | |
| SCHEMBL30363500 | 0.79 | HPGD (0.49) | HPGDL3MBTL1MAPTALDH1A1CYP1A2 | |
| SCHEMBL10041963 | 0.79 | HPGD (0.49) | HPGDL3MBTL1MAPTALDH1A1CYP1A2 | |
| SCHEMBL8886079 | 0.76 | CYP19A1 (0.45) | HPGDL3MBTL1MAPTALDH1A1CYP1A2 | |
| SCHEMBL6181741 | 0.75 | HPGD (0.41) | HPGDL3MBTL1MAPTALDH1A1CYP1A2 | |
| SCHEMBL7170156 | 0.72 | CYP19A1 (0.52) | HPGDL3MBTL1CYP19A1 | |
| SCHEMBL12460878 | 0.72 | HPGD (0.39) | HPGDL3MBTL1MAPTALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113149907-A | Synthetic method of 3-bromo-1, 3,4, 5-tetrahydro-2H-1-benzazepin-2-one | 河南普美济华医药科技有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-113149907-A | Synthetic method of 3-bromo-1, 3,4, 5-tetrahydro-2H-1-benzazepin-2-one | 河南普美济华医药科技有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113149907-A | Synthetic method of 3-bromo-1, 3,4, 5-tetrahydro-2H-1-benzazepin-2-one | 河南普美济华医药科技有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-6951872-B2 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | JACOBSON IRINA C (US) | 2004-07-08 | — | — | US | disclosed |
| US-6710058-B2 | USE AS ANTICOAGULANT AGENTS FOR THERAPY AND PROPHYLAXIS OFTHROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-23 | — | — | US | disclosed |
| EP-1337251-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002102380-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-05 | — | — | US | disclosed |
| US-5783573-A | Pharmaceuticals which promote gastrointestinal blood circulation | SOLVAY PHARMACEUTICALS GMBH (DE) | 1998-07-21 | — | — | US | disclosed |
| US-5677297-A | ENZYME INHIBITOR FOR TREATING THE HEART FAILURE TO REDUCE THE CARDIAC PRESSURE, DIURETICS | SOLVAY PHARMACEUTICALS GMBH (DE) | 1997-10-14 | — | — | US | disclosed |
| US-4600534-A | Process and intermediates for manufacture of 3-(5-amino-1-carboxypentylamino)-tetrahydro-1-benzazepin-2-one-1-acetic acid | CIBA-GEIGY CORPORATION (US) | 1986-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | HPGD 1181/4885L3MBTL1 4275/4885MAPT 4826/4885 |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | HPGD 1181/4885L3MBTL1 4275/4885MAPT 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.